Targeted Protein Degradation Market Size, Share, Growth Analysis, By Type (Degronimids, Immunomodulatory Drugs (IMIDS)), By Therapeutic Area (Inflammatory Disorders, Neurological Disorders), By Route of Administration, By End Use By Region - Industry Forecast 2025-2032


Report ID: SQMIG35H2045 | Region: Global | Published Date: February, 2024
Pages: 157 |Tables: 121 |Figures: 78

Targeted Protein Degradation Market Insights

Targeted Protein Degradation Market size was valued at USD 640.85 Million in 2023 and is poised to grow from USD 810.03 Million in 2024 to USD 5278.11 Million by 2032, growing at a CAGR of 26.40% during the forecast period (2025-2032).

Targeted Protein Degradation is becoming popular since It is a relatively new approach to drug development that involves using small molecules to selectively eliminate disease causing proteins. It is considered that this approach has several advantages over traditional drug development methods. These advantages include broad applicability, greater selectivity, increased durability, potential for combination therapy, novel mode of action.

Targeted protein degradation is a cutting-edge approach to drug development that offers several potential advantages over conventional methods. One of the key advantages of targeted protein degradation is its broad applicability, allowing it to target a wide range of disease-causing proteins. This includes proteins that have previously been considered "undruggable" using traditional methods. The ability to target a wider range of proteins offers potential new treatments for a variety of diseases, including cancer and genetic disorders. By selectively degrading the specific proteins that cause disease, targeted protein degradation can potentially provide a more effective and specific treatment compared to traditional methods that target entire cells or tissues.

Moreover, the selectivity of targeted protein degradation is a significant advantage. Unlike traditional drugs that can have non-specific effects on cells or tissues, targeted protein degradation can specifically degrade only disease-causing proteins without affecting normal proteins. This reduces the risk of side effects and improves therapeutic efficacy. Another potential advantage of targeted protein degradation is the increased durability of the treatment. Targeted protein degraders can remain active in the body for longer periods of time than traditional drugs, resulting in prolonged therapeutic effects. This may reduce the frequency of dosing, improve patient compliance, and ultimately lead to better patient outcomes.

US Targeted Protein Degradation Market is poised to grow at a sustainable CAGR for the next forecast year.

Market snapshot - 2024-2031

Global Market Size

USD 485.9 million

Largest Segment

PROTACs (Proteolysis targeting chimeras.)

Fastest Growth

Molecular glues.

Growth Rate

23.6% CAGR

Global Targeted Protein Degradation Market 2021-2030 ($ Bn)
Country Share for North America Region- 2021 (%)

To get more reports on the above market click here to Buy The Report

Targeted Protein Degradation Market Segmental Analysis

Global Targeted Protein Degradation Market is segmented by type, therapeutic area, route of administration, end use and region. Based on type, the market is segmented into degronimids, immunomodulatory drugs (IMIDS), proteolysis-targeting chimeric molecules (PROTACS), sudden acquired retinal degeneration syndrome (SARDS), selective estrogen receptor degraders (SERDS) and others. Based on therapeutic area, the market is segmented into inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders and others. Based on route of administration, the market is segmented into oral, intravenous and others. Based on end use, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospital & clinical laboratories and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.  

Targeted Protein Degradation Market Analysis by Technology

By Technology, the global market is divided into many segments such as PROTACs (Proteolysis-Targeting Chimeras), LYTACs (Lysosome-Targeting Chimeras), and SNIPERs (Specific and Non-genetic IAP-dependent Protein ERasers), Molecular glues, and others. The targeted protein degradation market is currently dominated by PROTACs (Proteolysis-Targeting Chimeras) in terms of technology. PROTACs are small molecules that can recruit target proteins to E3 ubiquitin ligases, which then catalyze the ubiquitination and subsequent degradation of the target protein by the proteasome. PROTACs have gained significant attention in recent years due to their potential for selectively targeting disease-causing proteins, including those previously considered "undruggable" using traditional methods. As a result, many pharmaceutical companies are heavily investing in PROTAC research and development, driving the growth of the market.

The targeted protein degradation market is currently witnessing the fastest growth in the molecular glues technology segment. Unlike other targeted protein degradation technologies, such as PROTACs and molecular degraders, molecular glues utilize a simpler chemical structure to bring together a target protein and an E3 ubiquitin ligase, thereby promoting the ubiquitination and subsequent degradation of the target protein.Molecular glues have several advantages over other targeted protein degradation technologies, including their ability to degrade targets that are difficult to access using other methods. Recently, several companies have made significant advancements in molecular glue technology, which has attracted significant attention and investment in the field. As a result, the molecular glues segment is expected to experience rapid growth in the coming years.

Global Targeted Protein Degradation Market By technology 2021 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Targeted Protein Degradation Market Regional Insights

The targeted protein degradation market is currently dominated by North America, which holds the largest market share. This is attributed to the presence of numerous pharmaceutical and biotechnology companies in the region, as well as substantial investment in research and development activities.

However, the Asia Pacific region is anticipated to witness the highest growth rate in the targeted protein degradation market. The growth can be attributed to the rising investment in healthcare infrastructure and research and development in countries such as China, Japan, and India. Moreover, the region has a vast population with high unmet medical needs, which is driving the demand for novel therapies, including targeted protein degradation.

Global Targeted Protein Degradation Market By Geography, 2021-2030
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Targeted Protein Degradation Market Dynamics

Targeted Protein Degradation Market Drivers

Increasing Demand for Effective Cancer Treatment to Boost Market Growth

  • The market for targeted protein degradation is being driven by several factors, one of which is the high demand for more effective treatments for a variety of diseases. Diseases such as cancer, genetic disorders, and autoimmune diseases have a significant impact on patient health and quality of life, and there is a growing need for treatments that can address the underlying causes of these diseases. Targeted protein degradation has the potential for selectively targeting disease-causing proteins, which could result in more effective treatments with fewer side effects. This approach allows for the development of drugs that can specifically target the proteins responsible for disease while sparing healthy cells and tissues. This high degree of specificity could potentially reduce the risk of side effects and improve patient outcomes. Moreover, the ability to selectively target disease-causing proteins provides a potential solution for previously untreatable diseases, including those that have been considered "undruggable" using traditional methods. This creates new opportunities for drug development and offers hope for patients with few treatment options.

Targeted Protein Degradation Market Restraints

Complexity of Targeted Protein Degradation to Hinder Market Growth

  • One of the significant Restraints that the targeted protein degradation market faces is the complexity of this field. This approach requires a profound understanding of the structure and function of proteins, as well as advanced drug design and development capabilities. Developing new therapies using this approach can be a time-consuming and challenging process, which may slow down the progress in the field. Targeted protein degradation is a relatively new and complex field that involves developing drugs that can selectively degrade specific proteins within cells. These drugs are designed to take advantage of the cells' natural protein degradation machinery, which allows them to selectively target disease-causing proteins while leaving healthy cells unharmed. The process of developing targeted protein degradation drugs requires a deep understanding of protein structure and function, as well as the ability to design molecules that can bind to specific proteins and recruit the cells' degradation machinery. The complexity of targeted protein degradation can make it difficult to develop new therapies using this approach. Drug developers need to have a thorough understanding of the disease biology and the specific proteins involved in the disease process to design effective drugs. Additionally, they need to develop molecules that are potent, selective, and stable enough to be used as drugs. This can be a time-consuming and challenging process that requires a significant investment in research and development.

Request Free Customization of this report to help us to meet your business objectives.

Targeted Protein Degradation Market Competitive Landscape

It is considered that the competition within the global Targeted Protein Degradation market will intensify during the forecast period. This can be attributed to the entry of new players into the market and the increasing number of developments that are compatible with Targeted Protein Degradation. Presently, only a few major players are operating within the global market. However, this scenario is expected to change in the forthcoming years as more companies are likely to enter the market and offer their services.As the potential of Targeted Protein Degradation for the development of effective therapies for various diseases is becoming increasingly evident, there is a growing interest in this field. This has led to the entry of new players into the market, ranging from small startups to large pharmaceutical companies. With the increasing investments being made in research and development activities, more companies are expected to enter the market and offer their services, resulting in an intensified competitive landscape. Moreover, the growing number of developments compatible with Targeted Protein Degradation is expected to further increase the competition in the market. As more discoveries are made regarding the efficacy of this approach, it is expected to attract more companies, researchers, and investors to this field, thereby increasing the competition.

Targeted Protein Degradation Market Top Player’s Company Profiles

  • Arvinas (USA) 
  • Kymera Therapeutics (USA) 
  • Nurix Therapeutics (USA) 
  • C4 Therapeutics (USA) 
  • Foghorn Therapeutics (USA) 
  • Zymeworks (Canada) 
  • Bristol-Myers Squibb (USA) 
  • Pfizer (USA) 
  • AbbVie (USA) 
  • Sanofi (France) 
  • Roche (Switzerland) 
  • AstraZeneca (UK) 
  • Vertex Pharmaceuticals (USA) 
  • Amgen (USA) 
  • Takeda Pharmaceutical (Japan) 
  • Novartis (Switzerland) 
  • Gilead Sciences (USA) 
  • Merck & Co. (USA) 
  • Janssen Pharmaceuticals (Johnson & Johnson) (USA) 
  • BeiGene (China) 

Targeted Protein Degradation Market Recent Developments

  • In January 2022, Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel treatments for sarcomas, pediatric cancers, and other cancers, entered into a definitive agreement with DeuteRx. As per the agreement, Salarius will acquire an oral, small molecule portfolio for targeted protein degradation, including a lead drug candidate previously known as DRX-164, which Salarius has renamed as SP-3164. The acquisition also includes the related patent family, which includes issued composition of matter patents, as well as the opportunity to develop additional cancer-fighting assets in the targeted protein degradation space.

Targeted Protein Degradation Key Market Trends

  • One of the notable trends in the targeted protein degradation market is the growing emphasis on the development of oral drugs. This trend is driven by the increasing demand for more patient-friendly therapies that offer greater convenience and compliance. Oral drugs have a significant advantage over other forms of drug delivery, such as injections or infusions, as they can be easily taken at home and do not require patients to visit hospitals or clinics for treatment. To address this trend, several pharmaceutical companies are investing heavily in the research and development of oral drugs for targeted protein degradation. They are developing drugs that are capable of surviving the digestive tract and reaching the intended targets in the body. These drugs can also be formulated to release slowly in the body, ensuring a sustained therapeutic effect. The development of oral drugs for targeted protein degradation is expected to have a significant impact on patient care and drug development in the coming years. With these drugs, patients can receive effective treatment for a range of diseases from the comfort of their own homes, without the need for frequent hospital visits. Furthermore, the development of oral drugs is expected to increase patient compliance, which is critical for the success of any therapeutic intervention.

Targeted Protein Degradation Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.

Our analysis of the global market for targeted protein degradation indicates that this field is poised for significant growth during the forecast period, owing to several advantages it offers over traditional drug development approaches. For instance, targeted protein degradation has broad applicability and can be used to target a wide range of disease-causing proteins, including those that were previously considered "undruggable". This approach also provides greater selectivity and increased durability, which could result in more effective treatments with fewer side effects. Moreover, targeted protein degradation offers the potential for combination therapy, which is increasingly being recognized as a promising approach to treating complex diseases such as cancer. Additionally, the novel mode of action of targeted protein degradation makes it an attractive area of research for drug developers. Furthermore, the use of targeted protein degradation can improve the convenience and efficacy of oral drugs, as well as other investments for effective treatments. With the high expected rate of growth and demand, the targeted protein degradation market offers significant potential for new players to enter the market and contribute to its growth.

Report Metric Details
Market size value in 2022 USD 485.9 million
Market size value in 2031 USD 3271.25 million
Growth Rate 23.6%
Base year 2023
Forecast period 2024-2031
Forecast Unit (Value) USD Million
Segments covered
  • Type
    • Degronimids, Immunomodulatory Drugs (IMIDS), Proteolysis-Targeting Chimeric Molecules (PROTACS), Sudden Acquired Retinal Degeneration Syndrome (SARDS), Sudden Acquired Retinal Degeneration Syndrome (SARDS), Others
  • Therapeutic Area
    • Inflammatory Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders, Others
  • Route of Administration
    • Oral, Intravenous, Others
  • End Use
    • Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospital & Clinical Laboratories, Others
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Arvinas (USA) 
  • Kymera Therapeutics (USA) 
  • Nurix Therapeutics (USA) 
  • C4 Therapeutics (USA) 
  • Foghorn Therapeutics (USA) 
  • Zymeworks (Canada) 
  • Bristol-Myers Squibb (USA) 
  • Pfizer (USA) 
  • AbbVie (USA) 
  • Sanofi (France) 
  • Roche (Switzerland) 
  • AstraZeneca (UK) 
  • Vertex Pharmaceuticals (USA) 
  • Amgen (USA) 
  • Takeda Pharmaceutical (Japan) 
  • Novartis (Switzerland) 
  • Gilead Sciences (USA) 
  • Merck & Co. (USA) 
  • Janssen Pharmaceuticals (Johnson & Johnson) (USA) 
  • BeiGene (China) 

Targeted Protein Degradation Market Recent Developments

  • In January 2022, Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel treatments for sarcomas, pediatric cancers, and other cancers, entered into a definitive agreement with DeuteRx. As per the agreement, Salarius will acquire an oral, small molecule portfolio for targeted protein degradation, including a lead drug candidate previously known as DRX-164, which Salarius has renamed as SP-3164. The acquisition also includes the related patent family, which includes issued composition of matter patents, as well as the opportunity to develop additional cancer-fighting assets in the targeted protein degradation space.
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

 

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Targeted Protein Degradation Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Targeted Protein Degradation Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Targeted Protein Degradation Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Targeted Protein Degradation Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Targeted Protein Degradation Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Targeted Protein Degradation Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?
REQUEST FREE CUSTOMIZATION

FAQs

Global Targeted Protein Degradation Market size was valued at USD 485.9 million in 2022 and is poised to grow from USD 600.57 million in 2023 to USD 3271.25 million by 2031, growing at a CAGR of 23.6% during the forecast period (2024-2031). 

It is considered that the competition within the global Targeted Protein Degradation market will intensify during the forecast period. This can be attributed to the entry of new players into the market and the increasing number of developments that are compatible with Targeted Protein Degradation. Presently, only a few major players are operating within the global market. However, this scenario is expected to change in the forthcoming years as more companies are likely to enter the market and offer their services.As the potential of Targeted Protein Degradation for the development of effective therapies for various diseases is becoming increasingly evident, there is a growing interest in this field. This has led to the entry of new players into the market, ranging from small startups to large pharmaceutical companies. With the increasing investments being made in research and development activities, more companies are expected to enter the market and offer their services, resulting in an intensified competitive landscape. Moreover, the growing number of developments compatible with Targeted Protein Degradation is expected to further increase the competition in the market. As more discoveries are made regarding the efficacy of this approach, it is expected to attract more companies, researchers, and investors to this field, thereby increasing the competition. 'Arvinas (USA) ', 'Kymera Therapeutics (USA) ', 'Nurix Therapeutics (USA) ', 'C4 Therapeutics (USA) ', 'Foghorn Therapeutics (USA) ', 'Zymeworks (Canada) ', 'Bristol-Myers Squibb (USA) ', 'Pfizer (USA) ', 'AbbVie (USA) ', 'Sanofi (France) ', 'Roche (Switzerland) ', 'AstraZeneca (UK) ', 'Vertex Pharmaceuticals (USA) ', 'Amgen (USA) ', 'Takeda Pharmaceutical (Japan) ', 'Novartis (Switzerland) ', 'Gilead Sciences (USA) ', 'Merck & Co. (USA) ', 'Janssen Pharmaceuticals (Johnson & Johnson) (USA) ', 'BeiGene (China) ', 'In January 2022, Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel treatments for sarcomas, pediatric cancers, and other cancers, entered into a definitive agreement with DeuteRx. As per the agreement, Salarius will acquire an oral, small molecule portfolio for targeted protein degradation, including a lead drug candidate previously known as DRX-164, which Salarius has renamed as SP-3164. The acquisition also includes the related patent family, which includes issued composition of matter patents, as well as the opportunity to develop additional cancer-fighting assets in the targeted protein degradation space.'

The market for targeted protein degradation is being driven by several factors, one of which is the high demand for more effective treatments for a variety of diseases. Diseases such as cancer, genetic disorders, and autoimmune diseases have a significant impact on patient health and quality of life, and there is a growing need for treatments that can address the underlying causes of these diseases. Targeted protein degradation has the potential for selectively targeting disease-causing proteins, which could result in more effective treatments with fewer side effects. This approach allows for the development of drugs that can specifically target the proteins responsible for disease while sparing healthy cells and tissues. This high degree of specificity could potentially reduce the risk of side effects and improve patient outcomes. Moreover, the ability to selectively target disease-causing proteins provides a potential solution for previously untreatable diseases, including those that have been considered "undruggable" using traditional methods. This creates new opportunities for drug development and offers hope for patients with few treatment options.

One of the notable trends in the targeted protein degradation market is the growing emphasis on the development of oral drugs. This trend is driven by the increasing demand for more patient-friendly therapies that offer greater convenience and compliance. Oral drugs have a significant advantage over other forms of drug delivery, such as injections or infusions, as they can be easily taken at home and do not require patients to visit hospitals or clinics for treatment. To address this trend, several pharmaceutical companies are investing heavily in the research and development of oral drugs for targeted protein degradation. They are developing drugs that are capable of surviving the digestive tract and reaching the intended targets in the body. These drugs can also be formulated to release slowly in the body, ensuring a sustained therapeutic effect. The development of oral drugs for targeted protein degradation is expected to have a significant impact on patient care and drug development in the coming years. With these drugs, patients can receive effective treatment for a range of diseases from the comfort of their own homes, without the need for frequent hospital visits. Furthermore, the development of oral drugs is expected to increase patient compliance, which is critical for the success of any therapeutic intervention.

The targeted protein degradation market is currently dominated by North America, which holds the largest market share. This is attributed to the presence of numerous pharmaceutical and biotechnology companies in the region, as well as substantial investment in research and development activities.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Targeted Protein Degradation Market

Report ID: SQMIG35H2045

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE